Tourmaline Bio Stock Today
| TRML Stock | 26.73 0.48 1.83% |
Performance20 of 100
| Odds Of DistressLess than 35
|
Tourmaline Bio is selling for 26.73 as of the 6th of October 2024. This is a 1.83% up since the beginning of the trading day. The stock's lowest day price was 26.03. Tourmaline Bio has about a 35 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. Tourmaline Bio symbol was changed from TALS on 20th of October 2023. Equity ratings for Tourmaline Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of September 2024 and ending today, the 6th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of May 2021 | Category Healthcare | Classification Health Care |
Tourmaline Bio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 25.64 M outstanding shares of which 1.97 M shares are at this time shorted by private and institutional investors with about 15.93 trading days to cover. More on Tourmaline Bio
Moving together with Tourmaline Stock
| 0.73 | FHTX | Foghorn Therapeutics | PairCorr |
| 0.66 | BHC | Bausch Health Companies | PairCorr |
| 0.66 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Tourmaline Stock
Tourmaline Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Older Symbol | TALS | |||||||||||||||||||||||||||||||||||||||||||||
| CEO CoFounder | Sandeep MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Tourmaline Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tourmaline Bio's financial leverage. It provides some insight into what part of Tourmaline Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Tourmaline Bio (TRML) is traded on NASDAQ Exchange in USA. It is located in 27 West 24th Street, New York, NY, United States, 10010 and employs 70 people. Tourmaline Bio was previously known as Talaris Therapeutics and was traded on NASDAQ Exchange under the symbol TALS. Tourmaline Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 685.39 M. Tourmaline Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.64 M outstanding shares of which 1.97 M shares are at this time shorted by private and institutional investors with about 15.93 trading days to cover.
Tourmaline Bio generates negative cash flow from operations
Check Tourmaline Bio Probability Of Bankruptcy
Ownership AllocationTourmaline Bio shows a total of 25.64 Million outstanding shares. The majority of Tourmaline Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tourmaline Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tourmaline Bio. Please pay attention to any change in the institutional holdings of Tourmaline Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly one million eight hundred seven thousand seven hundred nineteen invesors are currently shorting Tourmaline Bio expressing very little confidence in its future performance.
Check Tourmaline Ownership Details
Tourmaline Bio Historical Income Statement
Tourmaline Stock Against Markets
Tourmaline Bio Corporate Management
| Susan Jones | Chief Officer | Profile | |
| Kimberly Piorkowski | Culture People | Profile | |
| Kristine OD | Medical Ophthalmology | Profile | |
| Dora Rau | Senior Quality | Profile | |
| Bradford JD | General Officer | Profile | |
| Dr MBA | Chief Officer | Profile |
Additional Information and Resources on Investing in Tourmaline Stock
When determining whether Tourmaline Bio is a strong investment it is important to analyze Tourmaline Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tourmaline Bio's future performance. For an informed investment choice regarding Tourmaline Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Return On Assets (0.17) | Return On Equity (0.23) |
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.